Ultragenyx Pharmaceutical Inc RARE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update
Ultragenyx Pharmaceutical to Sell Priority Review Voucher for $203 Million
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
Ultragenyx Pharmaceutical Rises After FDA Approves Fayuvi for Sanfilippo Syndrome Type A — Update
Trading Information
- Previous Close Price
- $15.43
- Day Range
- $15.32–16.51
- 52-Week Range
- $12.73–39.89
- Bid/Ask
- $15.92 / $16.48
- Shares Outstanding
- 101.92M
- Market Cap
- $1.67B
- Volume/Avg
- 3M / 4M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.27
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 1,371
- Website
- https://www.ultragenyx.com
Valuation
Metric | RARE |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.27 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | RARE |
|---|---|
Quick Ratio | 1.11 |
Current Ratio | 1.40 |
Interest Coverage | −5.63 |
Quick Ratio
RARE
Profitability
Metric | RARE |
|---|---|
Return on Assets (Normalized) | −30.18% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
RARE
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|$dcjyt | LOCK|P<b< | $140B | |||
| Moderna Inc MRNA | LOCK|RL?lR@ | LOCK|X> | $109B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|dh>v<<n | LOCK|@ll>$ | $95B | |||
| argenx SE ADR ARGX | LOCK|%bc%<H | LOCK|^L | $60B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|b&@^PM | LOCK|L! | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|?phlTgP | LOCK|$<B@m | $31B | |||
| Incyte Corp INCY | LOCK|hqGc>Pk | LOCK|rvF | $25B | |||
| BioNTech SE ADR BNTX | LOCK|>C&mkk | LOCK|>NB | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|&D?Yr!? | LOCK|zRdsy | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|%&Q%vL | LOCK|!%M | $16B |
United States